Inactivation of HTLV-III/LAV, hepatitis B and non-A/non-B viruses by pasteurization in human plasma protein preparations.
Pasteurization (heat treatment at +60 degrees C for 10 hours in solution) during the production of human plasma protein preparations has proved useful 1. to inactivate a broad spectrum of viruses and 2. in combination with stabilizers to leave the nativity of the products unaffected. Their efficacy has been experimentally tested for HTLV-III/LAV, Hepatitis B and non-A/non-B viruses. The following preparations were tested: with HTLV-III/LAV: Factor VIII, Factor IX, AT III, AHC and PPSB; with Hepatitis B virus: Factor VIII, Factor XIII, AT III, PPSB and Fibrinogen; with Hepatitis non-A/non-B virus: Factor VIII and AT III.
D000818:Animals; D001798:Blood Proteins / Q000592:standards* / Q000627:therapeutic use; D005260:Female; D006678:HIV / Q000254:growth & development / Q000302:isolation & purification*; D006526:Hepatitis C / Q000382:microbiology; D006518:Hepatitis Viruses / Q000254:growth & development / Q000302:isolation & purification*; D006358:Hot Temperature; D006801:Humans; D008297:Male; D002679:Pan troglodytes; D013242:Sterilization / Q000379:methods
D001798:Blood Proteins